Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
103,605
Roche Holding AG News & Analysis
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
stocks
10 best US blue-chip shares to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.10 | 48.60 | 0.57% |
| CAC 40 | 7,355.37 | 72.68 | 1.00% |
| DAX 40 | 19,984.32 | 135.55 | 0.68% |
| Dow JONES (US) | 42,992.21 | 333.59 | -0.77% |
| FTSE 100 | 8,149.78 | 12.79 | 0.16% |
| HKSE | 20,090.46 | 7.83 | -0.04% |
| NASDAQ | 19,722.03 | 298.33 | -1.49% |
| Nikkei 225 | 40,281.16 | 713.10 | 1.80% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 5,970.84 | 66.75 | -1.11% |
| S&P/ASX 200 | 8,261.80 | 40.90 | 0.50% |
| SSE Composite Index | 3,400.14 | 2.07 | 0.06% |